PMID- 35691972
OWN - NLM
STAT- MEDLINE
DCOM- 20220916
LR  - 20220921
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 43
IP  - 10
DP  - 2022 Oct
TI  - A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, 
      focusing on sleep disturbances and activities of daily living.
PG  - 5821-5837
LID - 10.1007/s10072-022-06159-9 [doi]
AB  - BACKGROUND: Rotigotine transdermal patch (TP) is a useful dopaminergic medication 
      for Parkinson's disease (PD). This meta-analysis attempted to evaluate the 
      effects of rotigotine TP on motor performance, activities of daily living (ADL) 
      limitations, and sleep disturbances in patients with PD. METHODS: Only randomized 
      controlled clinical trials (RCTs) with placebo design were included in this 
      study. The clinical outcomes, evaluated using the Unified Parkinson's Disease 
      Rating Scale (UPDRS III), UPDRS-II, UPDRS Part II + III, Parkinson's Disease 
      Sleep Scale (PDSS)-2, and adverse events (AEs) were evaluated. The Jadad scale 
      was used to evaluate study quality. RESULTS: A total of 16 RCTs with 4682 
      patients with PD were enrolled in this study. We found that rotigotine TP 
      significantly reduced the UPDRS-III, UPDRS-II, and UPDRS Part II + III scores, 
      indicating that rotigotine TP led to a significant amelioration of movement 
      symptoms and ADL limitations. Moreover, we found that rotigotine TP significantly 
      reduced PDSS-2 scores, suggesting that rotigotine TP led to a remarkable 
      improvement in sleep quality. Meanwhile, compared with the placebo group, 
      patients taking rotigotine TP did not have added incidence of AEs. CONCLUSION: 
      This study verified the efficacy and safety of rotigotine TP in treating PD. The 
      findings of the present study provide compelling evidence concerning and insight 
      into clinical usage of rotigotine TP. Future studies will focus on more non-motor 
      symptoms affected by rotigotine TP.
CI  - (c) 2022. Fondazione Societa Italiana di Neurologia.
FAU - Sun, Weibo
AU  - Sun W
AD  - Harbin Medical University, Harbin, China.
FAU - Wang, Qingyong
AU  - Wang Q
AD  - Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Yang, Tiansong
AU  - Yang T
AD  - First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 24 Heping 
      Road, Harbin, 150040, China. Yangtiansong2006@163.com.
FAU - Feng, Chuwen
AU  - Feng C
AD  - First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 24 Heping 
      Road, Harbin, 150040, China.
FAU - Qu, Yuanyuan
AU  - Qu Y
AD  - Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Yang, Yan
AU  - Yang Y
AD  - Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Li, Chaoran
AU  - Li C
AD  - Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Sun, Zhongren
AU  - Sun Z
AD  - Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Asakawa, Tetsuya
AU  - Asakawa T
AUID- ORCID: 0000-0002-2300-3509
AD  - Institute of Neurology, Guangdong Province, The Third People's Hospital of 
      Shenzhen, 29 Buji Bulan Road, Shenzhen, 518112, China. asakawat1971@gmail.com.
AD  - Research Base of Traditional Chinese Medicine Syndrome, Fujian University of 
      Traditional Chinese Medicine, Fuzhou, 350122, China. asakawat1971@gmail.com.
AD  - Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-Sen University, 
      Shenzhen, 518033, China. asakawat1971@gmail.com.
LA  - eng
GR  - 82074539/National foundation of natural science of China/
GR  - 81704170/National foundation of natural science of China/
GR  - LH2020H092/Natural Science of Heilongjiang Province/
GR  - ZHY2020-79/Research Fund Project for Chinese Medicine of Heilongjiang Province/
GR  - 2019XZZX-ZJ005/Research Fund for Construction of Evidence Based Medicine for 
      Chinese Medicine/
GR  - 20791025/the Japan Society for the Promotion of Science/
GR  - 24592157/the Japan Society for the Promotion of Science/
GR  - 15k10358/the Japan Society for the Promotion of Science/
GR  - 18K08991/the Japan Society for the Promotion of Science/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20220613
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
RN  - 0 (Dopamine Agonists)
RN  - 0 (Tetrahydronaphthalenes)
RN  - 0 (Thiophenes)
RN  - 87T4T8BO2E (rotigotine)
SB  - IM
MH  - Activities of Daily Living
MH  - Dopamine Agonists/adverse effects
MH  - Humans
MH  - *Parkinson Disease/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Sleep Wake Disorders/chemically induced
MH  - *Tetrahydronaphthalenes/adverse effects
MH  - *Thiophenes/adverse effects
OTO - NOTNLM
OT  - ADL
OT  - Adverse events
OT  - Motor symptoms
OT  - Parkinson's disease
OT  - Rotigotine transdermal patch
OT  - Sleep disturbances
EDAT- 2022/06/13 06:00
MHDA- 2022/09/17 06:00
CRDT- 2022/06/12 23:13
PHST- 2022/04/09 00:00 [received]
PHST- 2022/05/18 00:00 [accepted]
PHST- 2022/06/13 06:00 [pubmed]
PHST- 2022/09/17 06:00 [medline]
PHST- 2022/06/12 23:13 [entrez]
AID - 10.1007/s10072-022-06159-9 [pii]
AID - 10.1007/s10072-022-06159-9 [doi]
PST - ppublish
SO  - Neurol Sci. 2022 Oct;43(10):5821-5837. doi: 10.1007/s10072-022-06159-9. Epub 2022 
      Jun 13.